Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference
05 Setembro 2023 - 9:00AM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced management will participate
in the Morgan Stanley 21st Annual Global Healthcare Conference with
a fireside chat on Wednesday, Sept. 13, 2023 at 2:15 p.m. EDT.
On Sept. 19, Myriad will host an in-person Investor Day at the
newly constructed Dr. Walter Gilbert Innovation Center in South San
Francisco. Paul J. Diaz, president and CEO, and other members of
the Myriad executive leadership team will discuss commercialization
strategies, clinical advancement and new product pipeline, and
long-term financial goals.
The Morgan Stanley fireside chat will be available on Myriad’s
website at investor.myriad.com. For those unable to attend Myriad’s
Investor Day, the presentation and Q&A will also be available
at investor.myriad.com.
About Myriad GeneticsMyriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Media Contact:Glenn Farrell(385)
318-3718PR@myriad.com |
Investor Contact:Matt Scalo(801)
584-3532IR@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Myriad Genetics (NASDAQ:MYGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024